Pharmaceuticals, Biotechnology and Life Sciences
Allergan has announced that the latest addition to the Juvederm collection of fillers, Juvederm Volbella XC, is now available to physicians and patients for use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as “lipstick lines”, in adults over the age of 21.
Allergan has announced a collaboration with SonarMD on the development of clinical decision support (CDS) and patient engagement tools which can be used to facilitate physician identification of patients suffering from Irritable Bowel Syndrome with Diarrhea (IBS-D) in clinical practice and monitor their treatment outcomes.
Horizon Pharma, with its wholly owned subsidiaries, Horizon Pharma, Inc. and Horizon Pharma USA, Inc., intends to offer $300 million aggregate principal amount of senior notes due 2024, and to borrow $375 million.
Important clinical study results from one of Eli Lilly and Company’s ongoing immuno-oncology collaborations with Merck (known as MSD outside…
Pfizer, which was considering splitting itself for more than two years, said on Monday it would not do so, prompting shareholders to expect more deals that could bolster its roster of new medicines.
AstraZeneca and MedImmune, its global biologics research and development arm, on Wednesday announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for durvalumab (MEDI4736), an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1), for the treatment of patients with PD-L1 positive inoperable or metastatic urothelial bladder cancer whose tumour has progressed during or after one standard platinum-based regimen.
Funding for tuberculosis research fell $1.3 billion short of global targets last year, threatening worldwide goals to eliminate the disease between 2030 and 2035, researchers said on Monday.
Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Sosei Group’s subsidiary Heptares, for the treatment of migraine.
Allergan has agreed with the New York State Attorney General’s Office to end the litigation under Section 2 of the Sherman Act, and other statutes with the Attorney General over the decision of Forest Laboratories
Pfizer Inc on Monday said it would buy Botox maker Allergan Plc in a deal worth $160 billion (£106 billion) to slash its U.S. tax bill, rekindling a fierce political debate over the financial manoeuvre.